EUVIMEDEUVIMED entdecken
Crossref

Clinicopathological and Prognostic Implications of Circulating MicroRNA-429 in Breast Cancer Patients

Shivangini Sharma, Taniya Suryavanshi, Preeti Agarwal, Alok Singh, Sameer Gupta, Ajay Kumar Singh, Kulranjan Singh, Vandana Solanki, Shalini Bhalla

Annals of African Medicine · 14.08.2026

DOI: 10.4103/aam.aam_560_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of African Medicine, online erschienen am 14.08.2026. Verfasst von Shivangini Sharma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: MicroRNA-429 (miR-429), a member of the miR-200 family, has been implicated in epithelial–mesenchymal transition and tumor progression, yet its clinicopathological significance in breast cancer remains unclear. This study aimed to evaluate serum miR-429 expression in treatment-naïve breast cancer patients and correlate its levels with detailed histopathological variables, molecular subtype, treatment response, and outcome. Materials and Methods: In this prospective study, serum samples from 49 invasive ductal carcinoma (IDC- no special type [NST]) patients and 49 age-matched healthy controls were analyzed by quantitative real-time polymerase chain reaction. Clinicopathological data (tumor grade, receptor status, lymphovascular invasion [LVI], nodal status, mitosis, tumor-infiltrating lymphocytes, necrosis, and subtype) and treatment response (Response Evaluation Criteria in Solid Tumors [RECIST] v1.1) were recorded. Resection specimens were evaluated for residual cancer burden (RCB). Results: Mean serum miR-429 levels were significantly lower in cases than controls (0.92 ± 0.53 vs. 1.24 ± 0.55; t = 2.892, P = 0.005). Receiver operating characteristic analysis showed an area under the curve of 0.649 (95% confidence interval: 0.540–0.758; P = 0.011) with 67.3% sensitivity and specificity at a cut-off of

Schlagwörter

Stichwörter der Autor:innen

BiomarkersBiomarqueursbreast cancercancer du seincharge résiduelle tumoralecirculating microRNAsinvasion lymphovasculairelymphovascular invasionmiR-429microARN circulantsresidual cancer burden

Autor:innen und Institutionen

  • Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India.
  • Department of Surgical Oncology, King George's Medical University, Lucknow, Uttar Pradesh, India.
  • Department of Endocrine Surgery, King George's Medical University, Lucknow, Uttar Pradesh, India.
  • Department of Obs and Gynae, King George's Medical University, Lucknow, Uttar Pradesh, India.

Zitieren

APA

Sharma, S., Suryavanshi, T., Agarwal, P., Singh, A., Gupta, S., Singh, A. K., Singh, K., Solanki, V., & Bhalla, S. (2026). Clinicopathological and Prognostic Implications of Circulating MicroRNA-429 in Breast Cancer Patients. Annals of African Medicine. https://doi.org/10.4103/aam.aam_560_26

Vancouver

Sharma S, Suryavanshi T, Agarwal P, Singh A, Gupta S, Singh AK, et al. Clinicopathological and Prognostic Implications of Circulating MicroRNA-429 in Breast Cancer Patients. Annals of African Medicine. 2026. doi:10.4103/aam.aam_560_26

BibTeX
@article{Sharma2026,
  author = {Sharma, Shivangini and Suryavanshi, Taniya and Agarwal, Preeti and Singh, Alok and Gupta, Sameer and Singh, Ajay Kumar and Singh, Kulranjan and Solanki, Vandana and Bhalla, Shalini},
  title = {Clinicopathological and Prognostic Implications of Circulating MicroRNA-429 in Breast Cancer Patients},
  journal = {Annals of African Medicine},
  year = {2026},
  doi = {10.4103/aam.aam_560_26}
}
Kostenlos starten →